Challenge: How Can We Help People Prevent, Detect, and Manage Chronic Diseases, Especially in Resource-Limited Settings? 

Solution: Nightingale Health

Nightingale’s biomarker analysis platform combines low-cost and high scalability by measuring over 220 biomarkers from a single blood sample. By measuring broad biological data routinely, Nightingale produces more accurate analysis so that health care providers can predict individual risk, and prevent chronic diseases before their onset.  

About Teemu

Teemu Suna is CEO and Co-Founder of Nightingale Health, a pioneering Finnish healthcare company aiming to change global healthcare in chronic diseases with its blood testing re-invention. Suna is a true doer who has transformed a scientific, technology-centric innovation into a high-growth, globally operating company aiming to solve one of the world’s biggest health problems. He has gathered investments of 10M USD in two years to accelerate the mission of Nightingale Health Ltd. He aims for tangible improvements in global healthcare and believes that the status quo does not suffice – there is always a better way. Previously Suna worked for 15 years in engineering and management positions in information technology and has pioneered in several areas of healthcare IT. He is an expert in information management & technology, healthcare applications, biomedical applications and innovation leadership. Prior to joining Nightingale Health as CEO in 2014, Suna worked as CTO at Fujitsu Finland.